Annual Cash & Cash Equivalents
$9.56 M
-$10.30 M-51.85%
December 31, 2023
Summary
- As of February 8, 2025, CLRB annual cash & cash equivalents is $9.56 million, with the most recent change of -$10.30 million (-51.85%) on December 31, 2023.
- During the last 3 years, CLRB annual cash & cash equivalents has fallen by -$47.60 million (-83.27%).
- CLRB annual cash & cash equivalents is now -83.27% below its all-time high of $57.17 million, reached on December 31, 2020.
Performance
CLRB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$34.26 M
+$8.39 M+32.45%
September 30, 2024
Summary
- As of February 8, 2025, CLRB quarterly cash and cash equivalents is $34.26 million, with the most recent change of +$8.39 million (+32.45%) on September 30, 2024.
- Over the past year, CLRB quarterly cash and cash equivalents has increased by +$24.70 million (+258.22%).
- CLRB quarterly cash and cash equivalents is now -40.06% below its all-time high of $57.17 million, reached on December 31, 2020.
Performance
CLRB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CLRB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -51.9% | +258.2% |
| 3 y3 years | -83.3% | -15.1% |
| 5 y5 years | -27.8% | +157.6% |
CLRB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -73.2% | at low | -14.4% | +564.9% |
| 5 y | 5-year | -83.3% | at low | -40.1% | +564.9% |
| alltime | all time | -83.3% | +1319.8% | -40.1% | >+9999.0% |
Cellectar Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $34.26 M(+32.5%) |
| Jun 2024 | - | $25.87 M(-35.4%) |
| Mar 2024 | - | $40.03 M(+318.5%) |
| Dec 2023 | $9.56 M(-51.9%) | $9.56 M(-49.6%) |
| Sep 2023 | - | $18.99 M(+268.5%) |
| Jun 2023 | - | $5.15 M(-59.4%) |
| Mar 2023 | - | $12.68 M(-36.2%) |
| Dec 2022 | $19.87 M(-44.4%) | $19.87 M(+11.7%) |
| Sep 2022 | - | $17.79 M(-28.3%) |
| Jun 2022 | - | $24.81 M(-19.0%) |
| Mar 2022 | - | $30.63 M(-14.2%) |
| Dec 2021 | $35.70 M(-37.5%) | $35.70 M(-11.5%) |
| Sep 2021 | - | $40.34 M(-13.8%) |
| Jun 2021 | - | $46.78 M(-12.8%) |
| Mar 2021 | - | $53.63 M(-6.2%) |
| Dec 2020 | $57.17 M(+438.5%) | $57.17 M(+203.4%) |
| Sep 2020 | - | $18.84 M(-16.1%) |
| Jun 2020 | - | $22.45 M(+216.6%) |
| Mar 2020 | - | $7.09 M(-33.2%) |
| Dec 2019 | $10.61 M(-19.9%) | $10.61 M(-20.2%) |
| Sep 2019 | - | $13.30 M(-21.1%) |
| Jun 2019 | - | $16.85 M(+60.7%) |
| Mar 2019 | - | $10.49 M(-20.9%) |
| Dec 2018 | $13.26 M(+32.5%) | $13.26 M(-19.0%) |
| Sep 2018 | - | $16.37 M(+291.6%) |
| Jun 2018 | - | $4.18 M(-38.7%) |
| Mar 2018 | - | $6.82 M(-31.8%) |
| Dec 2017 | $10.01 M(-12.6%) | $10.01 M(+76.7%) |
| Sep 2017 | - | $5.66 M(-31.9%) |
| Jun 2017 | - | $8.31 M(-26.0%) |
| Mar 2017 | - | $11.24 M(-1.8%) |
| Dec 2016 | $11.44 M(+196.7%) | $11.44 M(+102.7%) |
| Sep 2016 | - | $5.65 M(-28.7%) |
| Jun 2016 | - | $7.92 M(+315.1%) |
| Mar 2016 | - | $1.91 M(-50.5%) |
| Dec 2015 | $3.86 M(-59.1%) | $3.86 M(+56.0%) |
| Sep 2015 | - | $2.47 M(-48.8%) |
| Jun 2015 | - | $4.83 M(-31.2%) |
| Mar 2015 | - | $7.03 M(-25.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $9.42 M(+289.6%) | $9.42 M(-18.6%) |
| Sep 2014 | - | $11.58 M(+611.9%) |
| Jun 2014 | - | $1.63 M(-57.3%) |
| Mar 2014 | - | $3.81 M(+57.5%) |
| Dec 2013 | $2.42 M(-48.3%) | $2.42 M(-52.7%) |
| Sep 2013 | - | $5.11 M(-12.3%) |
| Jun 2013 | - | $5.83 M(-25.9%) |
| Mar 2013 | - | $7.86 M(+68.1%) |
| Dec 2012 | $4.68 M(-15.0%) | $4.68 M(-16.4%) |
| Sep 2012 | - | $5.60 M(-21.7%) |
| Jun 2012 | - | $7.15 M(+88.7%) |
| Mar 2012 | - | $3.79 M(-31.2%) |
| Dec 2011 | $5.51 M(+717.3%) | $5.51 M(+246.1%) |
| Sep 2011 | - | $1.59 M(-52.0%) |
| Jun 2011 | - | $3.31 M(+221.4%) |
| Mar 2011 | - | $1.03 M(+53.0%) |
| Dec 2010 | $673.70 K(-92.3%) | $673.70 K(-80.0%) |
| Sep 2010 | - | $3.37 M(-0.9%) |
| Jun 2010 | - | $3.39 M(-39.5%) |
| Mar 2010 | - | $5.61 M(-36.0%) |
| Dec 2009 | $8.77 M(+594.6%) | $8.77 M(+57.5%) |
| Sep 2009 | - | $5.57 M(+23.9%) |
| Jun 2009 | - | $4.49 M(-35.6%) |
| Mar 2009 | - | $6.97 M(+452.4%) |
| Dec 2008 | $1.26 M(-87.0%) | $1.26 M(-70.0%) |
| Sep 2008 | - | $4.21 M(-23.9%) |
| Jun 2008 | - | $5.52 M(-15.0%) |
| Mar 2008 | - | $6.50 M(-33.3%) |
| Dec 2007 | $9.74 M(-2.0%) | $9.74 M(-36.2%) |
| Sep 2007 | - | $15.27 M(-20.8%) |
| Jun 2007 | - | $19.29 M(+148.2%) |
| Mar 2007 | - | $7.77 M(-21.8%) |
| Dec 2006 | $9.94 M(+132.9%) | $9.94 M(-15.1%) |
| Sep 2006 | - | $11.71 M(-27.3%) |
| Jun 2006 | - | $16.11 M(-7.2%) |
| Mar 2006 | - | $17.36 M(+306.9%) |
| Dec 2005 | $4.27 M | $4.27 M(-11.7%) |
| Sep 2005 | - | $4.83 M(+144.0%) |
| Jun 2005 | - | $1.98 M(>+9900.0%) |
| Mar 2005 | - | $100.00 |
FAQ
- What is Cellectar Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cellectar Biosciences?
- What is Cellectar Biosciences annual cash & cash equivalents year-on-year change?
- What is Cellectar Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cellectar Biosciences?
- What is Cellectar Biosciences quarterly cash and cash equivalents year-on-year change?
What is Cellectar Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of CLRB is $9.56 M
What is the all time high annual cash & cash equivalents for Cellectar Biosciences?
Cellectar Biosciences all-time high annual cash & cash equivalents is $57.17 M
What is Cellectar Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, CLRB annual cash & cash equivalents has changed by -$10.30 M (-51.85%)
What is Cellectar Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CLRB is $34.26 M
What is the all time high quarterly cash and cash equivalents for Cellectar Biosciences?
Cellectar Biosciences all-time high quarterly cash and cash equivalents is $57.17 M
What is Cellectar Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, CLRB quarterly cash and cash equivalents has changed by +$24.70 M (+258.22%)